BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23547049)

  • 1. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.
    Fedorchenko O; Stiefelhagen M; Peer-Zada AA; Barthel R; Mayer P; Eckei L; Breuer A; Crispatzu G; Rosen N; Landwehr T; Lilienthal N; Möllmann M; Montesinos-Rongen M; Heukamp L; Dürig J; Hallek M; Fingerle-Rowson G; Herling M
    Blood; 2013 May; 121(20):4126-36. PubMed ID: 23547049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.
    Herishanu Y; Gibellini F; Njuguna N; Hazan-Halevy I; Farooqui M; Bern S; Keyvanfar K; Lee E; Wilson W; Wiestner A
    Leuk Lymphoma; 2011 Sep; 52(9):1758-69. PubMed ID: 21649540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Gutjahr JC; Szenes E; Tschech L; Asslaber D; Schlederer M; Roos S; Yu X; Girbl T; Sternberg C; Egle A; Aberger F; Alon R; Kenner L; Greil R; Orian-Rousseau V; Hartmann TN
    Blood; 2018 Mar; 131(12):1337-1349. PubMed ID: 29352038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
    Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
    Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.
    Pedersen IM; Kitada S; Leoni LM; Zapata JM; Karras JG; Tsukada N; Kipps TJ; Choi YS; Bennett F; Reed JC
    Blood; 2002 Sep; 100(5):1795-801. PubMed ID: 12176902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
    Filip AA; Ciseł B; Wąsik-Szczepanek E
    Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
    Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
    Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
    Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells.
    Bottardi S; Guieze R; Bourgoin V; Fotouhi-Ardakani N; Dougé A; Darracq A; Lakehal YA; Berger MG; Mollica L; Bay JO; Omichinski JG; Milot E
    Exp Hematol; 2020 Aug; 88():68-82.e5. PubMed ID: 32682001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.
    Zhang S; Wu CC; Fecteau JF; Cui B; Chen L; Zhang L; Wu R; Rassenti L; Lao F; Weigand S; Kipps TJ
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6127-32. PubMed ID: 23530247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
    Balakrishnan K; Burger JA; Fu M; Doifode T; Wierda WG; Gandhi V
    Neoplasia; 2014 Dec; 16(12):1036-46. PubMed ID: 25499217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
    Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
    Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.
    Smit LA; Hallaert DY; Spijker R; de Goeij B; Jaspers A; Kater AP; van Oers MH; van Noesel CJ; Eldering E
    Blood; 2007 Feb; 109(4):1660-8. PubMed ID: 17038534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.
    D'Abundo L; Callegari E; Bresin A; Chillemi A; Elamin BK; Guerriero P; Huang X; Saccenti E; Hussein EMAA; Casciano F; Secchiero P; Zauli G; Calin GA; Russo G; Lee LJ; Croce CM; Marcucci G; Sabbioni S; Malavasi F; Negrini M
    Oncogene; 2017 Nov; 36(47):6617-6626. PubMed ID: 28783166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.